Cargando…

Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer

Deciphering principles of inter-tumoral heterogeneity is crucial for refinement of precision oncology. We have recently demonstrated that ‘oncogenic cooperation‘ between somatic mutations and regulatory germline variants can serve as a major cause for inter-tumoral heterogeneity, suggesting the requ...

Descripción completa

Detalles Bibliográficos
Autores principales: Musa, Julian, Grünewald, Thomas G. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961672/
https://www.ncbi.nlm.nih.gov/pubmed/31993496
http://dx.doi.org/10.1080/23723556.2019.1682924
_version_ 1783488031751143424
author Musa, Julian
Grünewald, Thomas G. P.
author_facet Musa, Julian
Grünewald, Thomas G. P.
author_sort Musa, Julian
collection PubMed
description Deciphering principles of inter-tumoral heterogeneity is crucial for refinement of precision oncology. We have recently demonstrated that ‘oncogenic cooperation‘ between somatic mutations and regulatory germline variants can serve as a major cause for inter-tumoral heterogeneity, suggesting the requirement of integrating the regulatory genome into ‘omics‘-based precision oncology.
format Online
Article
Text
id pubmed-6961672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69616722020-09-28 Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer Musa, Julian Grünewald, Thomas G. P. Mol Cell Oncol Author's Views Deciphering principles of inter-tumoral heterogeneity is crucial for refinement of precision oncology. We have recently demonstrated that ‘oncogenic cooperation‘ between somatic mutations and regulatory germline variants can serve as a major cause for inter-tumoral heterogeneity, suggesting the requirement of integrating the regulatory genome into ‘omics‘-based precision oncology. Taylor & Francis 2019-11-06 /pmc/articles/PMC6961672/ /pubmed/31993496 http://dx.doi.org/10.1080/23723556.2019.1682924 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Musa, Julian
Grünewald, Thomas G. P.
Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
title Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
title_full Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
title_fullStr Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
title_full_unstemmed Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
title_short Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
title_sort interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961672/
https://www.ncbi.nlm.nih.gov/pubmed/31993496
http://dx.doi.org/10.1080/23723556.2019.1682924
work_keys_str_mv AT musajulian interactionbetweensomaticmutationsandgermlinevariantscontributestoclinicalheterogeneityincancer
AT grunewaldthomasgp interactionbetweensomaticmutationsandgermlinevariantscontributestoclinicalheterogeneityincancer